Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1989 1
1990 3
1991 2
1992 7
1993 3
1994 1
1995 7
1996 4
1997 4
1998 3
1999 6
2000 2
2001 3
2002 7
2003 7
2004 3
2005 5
2006 3
2007 6
2008 5
2009 5
2011 5
2012 2
2013 2
2014 3
2015 2
2016 1
2017 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants.
Bhardwaj R, Stringfellow JC, Morris B, Croop RS, Bertz RJ. Bhardwaj R, et al. Headache. 2023 May;63(5):652-662. doi: 10.1111/head.14512. Epub 2023 May 4. Headache. 2023. PMID: 37140071 Clinical Trial.
OBJECTIVE: To assess the effect of single and multiple doses of rimegepant 75 mg dose on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol (EE)/norgestimate (NGM) in healthy females of childbearing potential or non-menopausal females …
OBJECTIVE: To assess the effect of single and multiple doses of rimegepant 75 mg dose on the pharmacokinetics of an oral contraceptive conta …
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Lucky AW, et al. J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):746-54. doi: 10.1016/s0190-9622(97)70112-9. J Am Acad Dermatol. 1997. PMID: 9366821 Clinical Trial.
OBJECTIVE: Our purpose was to evaluate the efficacy of a triphasic, combination OC (ORTHO TRI-CYCLEN [Ortho-McNeil Pharmaceutical, Raritan, N.J.], norgestimate/ethinyl estradiol) compared with placebo in the treatment of moderate acne vulgaris. ...Each month …
OBJECTIVE: Our purpose was to evaluate the efficacy of a triphasic, combination OC (ORTHO TRI-CYCLEN [Ortho-McNeil Pharmaceutical, Raritan, …
Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Redmond GP, et al. Obstet Gynecol. 1997 Apr;89(4):615-22. doi: 10.1016/S0029-7844(97)00059-8. Obstet Gynecol. 1997. PMID: 9083323 Clinical Trial.
OBJECTIVE: To evaluate the efficacy of a triphasic, combination oral contraceptive (OC), (norgestimate-ethinyl estradiol), in comparison with placebo in the treatment of moderate acne vulgaris. METHODS: Two hundred fifty women were enrolled in a multicenter, …
OBJECTIVE: To evaluate the efficacy of a triphasic, combination oral contraceptive (OC), (norgestimate-ethinyl estradiol
Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
Gauthier A, Upmalis D, Dain MP. Gauthier A, et al. Acta Obstet Gynecol Scand Suppl. 1992;156:27-32. doi: 10.3109/00016349209156512. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1324554 Clinical Trial.
The safety and efficacy of the triphasic oral contraceptive agent containing norgestimate and ethinyl estradiol were evaluated in a 12-month study of 661 women. ...The safety and efficacy of the triphasic oral contraceptive (OC) containing norgestimate
The safety and efficacy of the triphasic oral contraceptive agent containing norgestimate and ethinyl estradiol were ev …
The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women.
Runnebaum B, Grunwald K, Rabe T. Runnebaum B, et al. Am J Obstet Gynecol. 1992 Jun;166(6 Pt 2):1963-8. doi: 10.1016/0002-9378(92)91396-r. Am J Obstet Gynecol. 1992. PMID: 1605286 Clinical Trial.
The efficacy and tolerability of a new oral contraceptive, norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol; Cilag GmbH Research, Sulzbach, Germany) were examined in an open-label study of …
The efficacy and tolerability of a new oral contraceptive, norgestimate/ethinyl estradiol (250 micrograms of norgest
Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.
Zhu B, Nestorov I, Zhao G, Meka V, Leahy M, Kam J, Sheikh SI. Zhu B, et al. Clin Pharmacol Drug Dev. 2017 Nov;6(6):604-613. doi: 10.1002/cpdd.377. Epub 2017 Aug 7. Clin Pharmacol Drug Dev. 2017. PMID: 28783872 Free PMC article. Clinical Trial.
This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combined oral contraceptive (OC; norgestimate 250 mug, ethinyl estradiol 35 mug). Forty-six healthy women were enrolled; 32 …
This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combi …
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R. Bifano M, et al. Antivir Ther. 2014;19(5):511-9. doi: 10.3851/IMP2718. Epub 2013 Dec 17. Antivir Ther. 2014. PMID: 24343001 Clinical Trial.
The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate (Ortho Tri-Cyclen()). METHODS: In this open-label single-sequence study, 20 heal …
The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive contain …
Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
Andolsek KM. Andolsek KM. Acta Obstet Gynecol Scand Suppl. 1992;156:22-6. doi: 10.3109/00016349209156511. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1324553 Clinical Trial.
Effective cycle control was demonstrated based on two multicenter, 2-year studies of the triphasic oral contraceptive (OC) agent containing the new progestin norgestimate. The estrogen in this OC is ethinyl estradiol. These open-label Phase III studies were c …
Effective cycle control was demonstrated based on two multicenter, 2-year studies of the triphasic oral contraceptive (OC) agent containing …
Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
Archer DF, Stanczyk FZ, Rubin A, Foegh M. Archer DF, et al. Contraception. 2012 Jun;85(6):595-601. doi: 10.1016/j.contraception.2011.10.006. Epub 2011 Nov 30. Contraception. 2012. PMID: 22133660 Clinical Trial.
BACKGROUND: This study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200-15, a transdermal contraceptive delivery system, compared with a combination oral contraceptive (COC) containing EE 35 mcg and norgestimate
BACKGROUND: This study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200-15, a t …
Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Patel G, King A, Dutta S, Korb S, Wade JR, Foulds P, Sumeray M. Patel G, et al. J Clin Pharmacol. 2016 Jan;56(1):47-55. doi: 10.1002/jcph.581. Epub 2015 Sep 10. J Clin Pharmacol. 2016. PMID: 26120010 Clinical Trial.
Two phase 1 open-label, randomized (1:1), 2-arm drug interaction studies in healthy subjects assessed the effects of atorvastatin and ethinyl estradiol (EE)/norgestimate, both weak CYP3A inhibitors, on lomitapide pharmacokinetics with staggered (separated by …
Two phase 1 open-label, randomized (1:1), 2-arm drug interaction studies in healthy subjects assessed the effects of atorvastatin and eth
100 results